Literature DB >> 27968732

Genetics of Schizophrenia: Historical Insights and Prevailing Evidence.

J van de Leemput1, J L Hess2, S J Glatt2, M T Tsuang1.   

Abstract

Schizophrenia's (SZ's) heritability and familial transmission have been known for several decades; however, despite the clear evidence for a genetic component, it has been very difficult to pinpoint specific causative genes. Even so genetic studies have taught us a lot, even in the pregenomic era, about the molecular underpinnings and disease-relevant pathways. Recurring themes emerged revealing the involvement of neurodevelopmental processes, glutamate regulation, and immune system differential activation in SZ etiology. The recent emergence of epigenetic studies aimed at shedding light on the biological mechanisms underlying SZ has provided another layer of information in the investigation of gene and environment interactions. However, this epigenetic insight also brings forth another layer of complexity to the (epi)genomic landscape such as interactions between genetic variants, epigenetic marks-including cross-talk between DNA methylation and histone modification processes-, gene expression regulation, and environmental influences. In this review, we seek to synthesize perspectives, including limitations and obstacles yet to overcome, from genetic and epigenetic literature on SZ through a qualitative review of risk factors and prevailing hypotheses. Encouraged by the findings of both genetic and epigenetic studies to date, as well as the continued development of new technologies to collect and interpret large-scale studies, we are left with a positive outlook for the future of elucidating the molecular genetic mechanisms underlying SZ and other complex neuropsychiatric disorders.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contributing biological mechanisms; DNA methylation; Epigenetics; GWAS; Genetics; Genomic complexity; Histone modification; Neurodevelopment; Prefrontal cortex; Schizophrenia

Mesh:

Year:  2016        PMID: 27968732     DOI: 10.1016/bs.adgen.2016.08.001

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  11 in total

Review 1.  The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2019-12-17       Impact factor: 3.575

Review 2.  Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.

Authors:  Amber Edinoff; Miriam T Ruoff; Yahya T Ghaffar; Arthur Rezayev; Devanshi Jani; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2020-09-14

Review 3.  Lumateperone for the Treatment of Schizophrenia.

Authors:  Amber Edinoff; Natalie Wu; Charles deBoisblanc; Catherine Olivia Feltner; Mariah Norder; Vesela Tzoneva; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2020-09-14

Review 4.  Early deviant behaviour as a dimension trait and endophenotype in schizophrenia.

Authors:  Johannes L Roos; Carla Kotzé
Journal:  S Afr J Psychiatr       Date:  2022-04-29       Impact factor: 1.242

5.  Uniting the neurodevelopmental and immunological hypotheses: Neuregulin 1 receptor ErbB and Toll-like receptor activation in first-episode schizophrenia.

Authors:  Szabolcs Kéri; Csilla Szabó; Oguz Kelemen
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

Review 6.  Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review.

Authors:  Laura Orsolini; Fabiola Sarchione; Federica Vellante; Michele Fornaro; Ilaria Matarazzo; Giovanni Martinotti; Alessandro Valchera; Marco Di Nicola; Alessandro Carano; Massimo Di Giannantonio; Giampaolo Perna; Luigi Olivieri; Domenico De Berardis
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

7.  Study on clinical characteristics and related factors of schizophrenic patients with intestinal obstruction.

Authors:  Mingchao Li; Ping Guo; Jihua Zeng; Chi Li; Qiuming Ji; Yunqing Zhao; Haiying Chen; Ying Wang; Yunjiao Hu; Lianzhong Liu
Journal:  BMC Gastroenterol       Date:  2022-01-06       Impact factor: 3.067

Review 8.  Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease.

Authors:  Irfan Ullah; Hashir Ali Awan; Alifiya Aamir; Mufaddal Najmuddin Diwan; Renato de Filippis; Sana Awan; Muhammad Irfan; Michele Fornaro; Antonio Ventriglio; Federica Vellante; Mauro Pettorruso; Giovanni Martinotti; Massimo Di Giannantonio; Domenico De Berardis
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

9.  Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.

Authors:  Ping Lin; Junyu Sun; Xiaoyan Lou; Dan Li; Yun Shi; Zhenhua Li; Peijun Ma; Ping Li; Shuzi Chen; Weifeng Jin; Shuai Liu; Qing Chen; Qiong Gao; Lili Zhu; Jie Xu; Mengyuan Zhu; Mengxia Wang; Kangyi Liang; Ling Zhao; Huabin Xu; Ke Dong; Qingtian Li; Xunjia Cheng; Jinghong Chen; Xiaokui Guo
Journal:  Gen Psychiatr       Date:  2022-02-23

10.  Elevated Serum Purine Levels in Schizophrenia: A Reverse Translational Study to Identify Novel Inflammatory Biomarkers.

Authors:  Zsüliet Kristóf; Mária Baranyi; Pál Tod; Paula Mut-Arbona; Kornél Demeter; István Bitter; Beáta Sperlágh
Journal:  Int J Neuropsychopharmacol       Date:  2022-08-16       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.